Regeneron Stock Story

REGN
 Stock
  

USD 619.70  10.93  1.73%   

Lets try to outline the odds of Regeneron Pharmaceuticals to fully recover from the latest slide as its shares went up 5.88%. This firm current daily volatility is 2.11 percent, with a beta of 0.73 and an alpha of -0.18 over DOW. As many of us are excited about cancer fighters, it is fair to outline Regeneron Pharmaceuticals. We will evaluate why we are still optimistic in anticipation of a recovery.
Published few days ago
View all stories for Regeneron Pharmaceuticals | View All Stories

Should we continue shadow Regeneron Pharmaceuticals (NASDAQ:REGN) executives?

Regeneron Pharmaceuticals currently holds roughly 7.05 B in cash with 8.51 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 65.44.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Regeneron Pharmaceuticals has an asset utilization ratio of 294.34 percent. This suggests that the company is making $2.94 for each dollar of assets. An increasing asset utilization means that Regeneron Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
Investing in Regeneron Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Regeneron Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Regeneron Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Regeneron Pharmaceuticals in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Regeneron Pharmaceuticals. Your research has to be compared to or analyzed against Regeneron Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Regeneron Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Regeneron Pharmaceuticals.

How important is Regeneron Pharmaceuticals's Liquidity

Regeneron Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Regeneron Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Regeneron Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Regeneron Pharmaceuticals's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Regeneron Pharmaceuticals, but it might be worth checking our own buy vs. sell analysis

Regeneron Pharmaceuticals Correlation with Peers

Investors in Regeneron can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Regeneron Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Regeneron Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Regeneron is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Regeneron for more details

Exercise or conversion by Marion McCourt of 1100 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Legal trades by Regeneron Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Regeneron insider trading alert for exercise of non-qualified stock option (right to buy) by Marion McCourt, EVP Commercial, on 2nd of August 2022. This event was filed by Regeneron Pharmaceuticals with SEC on 2022-08-02. Statement of changes in beneficial ownership - SEC Form 4. Marion McCourt currently serves as senior vice president and head of commercial of Regeneron Pharmaceuticals [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Regeneron Pharmaceuticals Investor Appetite?

Regeneron Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of -0.0271, which implies the firm had -0.0271% of return per unit of risk over the last 3 months. Macroaxis standpoint towards forecasting the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Regeneron Pharmaceuticals exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to check Regeneron Pharmaceuticals risk adjusted performance of (0.16), and Coefficient Of Variation of (877.59) to confirm the risk estimate we provide.
PFE
NNDM
INTC
VZ
MSFT
PFE
0.280.020.440.15
PFE
NNDM
0.28-0.580.10.07
NNDM
INTC
0.02-0.58-0.150.53
INTC
VZ
0.440.1-0.15-0.24
VZ
MSFT
0.150.070.53-0.24
MSFT
PFE
NNDM
INTC
VZ
MSFT
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Our take on today Regeneron Pharmaceuticals rise

Latest Information Ratio is up to -0.08. Price may slide again. Regeneron Pharmaceuticals exhibits very low volatility with skewness of -0.26 and kurtosis of 0.25. However, we advise investors to further study Regeneron Pharmaceuticals technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Regeneron Pharmaceuticals' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Regeneron Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Regeneron Pharmaceuticals Implied Volatility

Regeneron Pharmaceuticals' implied volatility exposes the market's sentiment of Regeneron Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Regeneron Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Regeneron Pharmaceuticals stock will not fluctuate a lot when Regeneron Pharmaceuticals' options are near their expiration.

Whereas some other companies in the biotechnology industry are either recovering or due for a correction, Regeneron Pharmaceuticals may not be performing as strong as the other in terms of long-term growth potentials. Taking everything into account, as of the 3rd of August 2022, we see that Regeneron Pharmaceuticals follows the market closely. The company is overvalued with very small probability of bankruptcy within the next 24 months. Our ongoing 90 days buy-sell recommendation on the company is Strong Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Regeneron Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com